Multiple Myeloma: all 3,712 studies
Page 3 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple MyelomaNot yet recruitingNCT07221032Phase 1
- Karyopharm Expanded Access Program for SelinexorAvailableNCT07215832
- Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical EvolutionRecruitingNCT07214324
- Study of HuL001 in Relapsed/Refractory Multiple Myeloma PatientsRecruitingNCT07210047Phase 1/2
- High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)RecruitingNCT07205523
- Selinexor Maintenance Post CAR-T Cell Therapy for Multiple MyelomaRecruitingNCT07200102Phase 1
- Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)RecruitingNCT07200089Phase 1
- Immune Adverse Events Registry in Onco-Hematologic Patients Treated With ImmunotherapyNot yet recruitingNCT07198958
- Self-administered Subcutaneous Daratumumab in Patients With Multiple MyelomaNot yet recruitingNCT07191379Phase 4
- Mozobil for Autologous Hematopoietic Stem Cell TransplantationRecruitingNCT07188090Phase 2
- IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07185490Early Phase 1
- A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07185477Early Phase 1
- Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple MyelomaRecruitingNCT07181941Phase 1/2
- Study of CM336 in Relapsed or Refractory Multiple Myeloma PatientsNot yet recruitingNCT07181239Phase 3
- Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple MyelomaRecruitingNCT07180992
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Phase 1
- Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma PatientsRecruitingNCT07169500Phase 1/2
- A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingNCT07149857Phase 2
- Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple MyelomaRecruitingNCT07139509Phase 1
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07138209Phase 3
- A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07116616Phase 1/2
- RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple MyelomaNot yet recruitingNCT07114432Phase 1
- RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic MalignanciesNot yet recruitingNCT07113496Phase 1
- GMMG Multiple Myeloma RegistryRecruitingNCT07111884
- Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.RecruitingNCT07107529Phase 2
- A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic MalignanciesNot yet recruitingNCT07107204Phase 1/2
- MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple MyelomaRecruitingNCT07106736Phase 2
- ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple MyelomaRecruitingNCT07106710Phase 2
- ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell LeukemiaRecruitingNCT07106684Phase 2
- A Study of Teclistamab and Mezigdomide in People With Multiple MyelomaRecruitingNCT07105059Phase 1
- An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological MalignanciesRecruitingNCT07101705Early Phase 1
- Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE TrialRecruitingNCT07101445Phase 4
- LCAR-F33S in Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07100067Not applicable
- A Study of Dara-RVd and Teclistamab-RVd in People With Multiple MyelomaRecruitingNCT07099391Phase 1/2
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07095452Phase 2/3
- Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerRecruitingNCT07094048Phase 4
- Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07093554Phase 1
- A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple MyelomaNot yet recruitingNCT07090954Phase 1/2
- Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney FailureRecruitingNCT07085728Phase 2
- Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical ResearchRecruitingNCT07085559Early Phase 1
- A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT07075185Phase 1
- A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)RecruitingNCT07073547Phase 1
- A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligibleNot yet recruitingNCT07070960Not applicable
- CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?Not yet recruitingNCT07070934Phase 2
- Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional ImmunotherapiesRecruitingNCT07051850
- Risk-adapted Therapeutic Strategy in +1q NDMMNot yet recruitingNCT07045168
- Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma PatientsRecruitingNCT07044427Not applicable
- Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste DisordersRecruitingNCT07040189Not applicable
- Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple MyelomaNot yet recruitingNCT07034755Not applicable
- Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaRecruitingNCT07032714Phase 1
- Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple MyelomaRecruitingNCT07032129Phase 1/2
- MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple MyelomaNot yet recruitingNCT07029776Phase 2
- Long-term Follow-up Registry Study of Equecabtagene Autoleucel InjectionRecruitingNCT07028970
- Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)RecruitingNCT07025005Phase 4
- A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma PatientsNot yet recruitingNCT07018271Not applicable
- Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple MyelomaRecruitingNCT07018050Phase 2
- The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsNot yet recruitingNCT07015021Not applicable
- Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their CaregiversRecruitingNCT07014865
- BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)Not yet recruitingNCT07009899Phase 2
- Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary InfiltrationRecruitingNCT07003568Phase 1
- Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary InfiltrationRecruitingNCT07003555Phase 1
- A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06999031Early Phase 1
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingNCT06997081Phase 2
- Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)RecruitingNCT06993675Phase 2
- A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06988488Phase 1/2
- "Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple MyelomaRecruitingNCT06988020Not applicable
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaRecruitingNCT06980480Phase 3
- Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and HypogammaglobulinemiaRecruitingNCT06976476Phase 2
- A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsRecruitingNCT06976437Early Phase 1
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingNCT06974786Phase 2
- Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain AmyloidosisRecruitingNCT06971380Phase 2
- Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCTNot yet recruitingNCT06963866Phase 2
- Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell LymphomaRecruitingNCT06961669Not applicable
- Mosaic Trial for Stem Cell Transplant RecipientsRecruitingNCT06960993Not applicable
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingNCT06953960Phase 1/2
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingNCT06948084Phase 2
- Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06940297Phase 2
- Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM PatientsRecruitingNCT06933277
- A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for TransplantRecruitingNCT06932562Phase 3
- Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)Not yet recruitingNCT06931704Phase 2
- A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple MyelomaNot yet recruitingNCT06925958Not applicable
- Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapyRecruitingNCT06920251Phase 2
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingNCT06918002Phase 3
- Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT06913192Phase 1
- CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT06913179Phase 1
- The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic TumorsRecruitingNCT06911710Phase 1/2
- Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After RelapseRecruitingNCT06910124Phase 2
- Addressing Social Determinants of Health Among Metro Detroit Cancer SurvivorsRecruitingNCT06908629Not applicable
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
- Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06896916Phase 1
- A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaNot yet recruitingNCT06895512Phase 3
- Whole Body MRI in OncologyRecruitingNCT06895291
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
- Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of PatientsNot yet recruitingNCT06888856
- LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06888752Not applicable
- Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple MyelomaNot yet recruitingNCT06880601Phase 2
- BCMA CAR-T for Dynamic High-risk Multiple MyelomaRecruitingNCT06880393Phase 2
- KPD Consolidation After ASCT in NDMM PatientsRecruitingNCT06879379Phase 2/3
- Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+RecruitingNCT06874530
- PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)RecruitingNCT06871176Not applicable